Key result
Acupuncture and moxibustion significantly improved the efficacy rate for treating heart failure compared to traditional treatment alone (OR 2.61; 95% CI 1.84-3.72; p<0.0001).
Why the study?
Although clinical reports exist on treating heart failure with acupuncture and moxibustion, its effectiveness had not been fully demonstrated.
Does acupuncture and moxibustion added to medication improve heart function in patients with heart failure?
Systematic Review (n=2,499)
Does acupuncture and moxibustion added to medication improve heart function in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Acupuncture and moxibustion as an adjunct to standard medication may improve surrogate markers of heart function and exercise capacity in heart failure patients, though the quality of evidence is limited by methodological flaws in the included trials.
Background . Acupuncture and moxibustion (A&M) has been used for treating heart failure in China since the Han Dynasty. This ancient therapy can be applied to many diseases according to the WHO recommendations. Although there are many clinical reports on the treatment of heart failure by A&M, its effectiveness is still not fully demonstrated. We aimed to systematically review the related randomized controlled trial (RCT) studies and conduct a meta-analysis. Methods . The PubMed, MEDLINE, EMBASE, AMED, CENTRAL, CNKI, Wanfang, and Weipu databases were searched electronically until December 2018. The data were extracted, and the risk of bias was evaluated. Meta-analysis, subgroup analysis, and metaregression were performed. Heart function was the main outcome assessed. The details of the intervention were also investigated. Results . Thirty-two RCTs involving 2499 patients were included. Most studies had an unclear risk regarding blinding and allocation concealment. Compared with the traditional treatment group, the experimental group had a higher efficacy rate (odds ratio (OR) = 2.61, 95% confidence interval (95%CI): = [1.84; 3.72], I 2 = 0%, p<0.0001) and a significantly improved left ventricular ejection fraction (LVEF) (mean difference (MD) = 6.34, 95%CI = [4.11, 8.57], I 2 = 93%, p<0.0001), cardiac output (CO) (MD = 1.02, 95%CI = [0.65, 1.39], I 2 = 94%, p<0.0001), 6-minute walk test (6MWT) (MD = 43.6, 95%CI = [37.43, 49.77], I 2 = 0%, p<0.0001), and reduced brain-type natriuretic peptide (BNP) (MD = −227.99, 95%CI = [−337.30, −118.68], I 2 = 96%, p<0.0001). Adverse events were inadequately reported in most studies. Conclusions . A&M may be a promising intervention as an adjunctive therapy to medication for treating heart failure. However, the evidence was inconclusive. Further large and rigorously designed RCTs are needed for verification.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2019) conducted a systematic review in Heart failure (n=2,499). Acupuncture and moxibustion vs. Traditional treatment was evaluated on Efficacy rate (OR 2.61, 95% CI 1.84-3.72, p=<0.0001). Acupuncture and moxibustion significantly improved the efficacy rate for treating heart failure compared to traditional treatment alone (OR 2.61; 95% CI 1.84-3.72; p<0.0001).
Synapse has enriched 10 related papers. Consider them for comparative context: